Open for inclusion

Cancer type Title Country
Breast cancer A Randomized, Phase 2 Study of the Efficacy and Tolerability of Veliparib in Combination With Temozolomide or Veliparib in Combination With Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Subjects With BRCA1 or BRCA2 Mutation NO
Breast cancer First in human study in HER2 positive primary breast cancer patient who are eligible for neoadjuvant chemotherapy DK
Breast cancer Intra-hepatic chemotherapy in patient with non-resectable liver mestastases from breast cancer. Only patients without extrahepatic disease are included DK
Breast cancer Intra-hepatic chemotherapy in patient with non-resectable liver metastases from breast cancer and limited extrahepatic disease DK
Breast cancer Phase Ib, Open-Label, Multicenter, Doseescalation Study followed by an Extension Phase to Evaluate the Safety, Pharmacokinetics and Activity of Ro5479599, a Glycoengineered Antibody Against Her3, Administered in combination with Pertuzumab and Paclitaxel DK
Breast cancer Pre-Operative Study of PF-4691502 With Letrozole Compared To Letrozole Alone In Patients With Early Breast Cancer SE
Cholangiocarcinoma A phase II trial evaluating intra-hepatic chemotherapy with oxaliplatin every second week in combination with systemic gemcitabine and capecitabine in combination with cetuximab in patient with non-resectable liver metastases from cholangiocarcinoma DK
Colorectal cancer A double blinded randomised three armed phase II trial of PledOx in two different doses in combination with FOLFOX6 compared to placebo + FOLFOX6 in patients with advanced metastatic colorectal (stage IV) cancer SE
Colorectal cancer A Phase lb/II Multi-center, Open-label, Dose Escalation Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in Patients With BRAF Mutant Metastatic Colorectal Cancer NO
Colorectal cancer Intra-hepatic and systemic chemotherapy with or without antibody for patients with non-resectable liver metastasis from solid tumours DK
Colorectal cancer Open-label , single-arm, phase II study of bevacizumab (Avastin) in combination with alternating Xeliri and Xelox as first-line treatment of patients with metastatic colorectal cancer FI
Colorectal cancer Potentially Resectable Metastatic Colorectal Cancer With Wild-type KRAS and BRAF: Alternating Chemotherapy Plus Cetuximab - A Randomised Phase II Trial NO
Colorectal cancer The international liver tumor group. Radiofrequency ablation versus stereotactic body radiation therapy for colorectal liver metastases: A randomized trial SE
Esophageal cancer Follow up of Phase I study of radiotherapy and platinum-Fluouracil based chemotherapy with cetuximab in locally advanced esopgael cancer DK
Gastric cancer Pazopanib in advanced gastrointestinal stromal tumors refractory to imatinib and sunutinib. A Non-comparative phase II multicenter study study by the Scandinavian Sarcoma Group FI
Gastric cancer Phase I-II study of traztuzumab combined with docetaxel, oxaliplatin and capecitabine in advanced or metastatic gastic or cardia cancer DK
Glioblastoma Electrochemotherapy as a Palliative Treatment for Brain Metastases DK
Head and Neck cancer A multicentre, open label, randomised phase II study with or without induction chemotherapy, combined with radiotherapy and cetuximab (Erbitux®®) in locally advanced unresectable squamous cell carcinoma of the head & neck with HPV positive tumors SE
Head and Neck cancer A Phase 1b/2 study of docetaxel with or without buparlisib as second line therapy for patients with advanced or metastatic squamous non-small cell lung cancer SE
Head and Neck cancer An open-label, non-randomised, multicentre phase 1/2 trial of RO5424802 given orally to non-small cell lung cancer patients who have ALK mutation and failed crizotinib treatment. SE
Hematological malignancies A Phase I Study of the Safety, Pharmacokinetics and Pharmacodynamics of Escalating Doses of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 inPatients with Advanced Hematological Malignancies DK
Leukemia A multicenter open randomised phase II study of the efficacy and safety of azacitidine alone or in combination with lenalidomide in high-risk myeloid disease (high-risk MDS and AML) with a karyotype including del(5q) DK
Leukemia A Multicentre Open Randomized Phase II Study of the Efficacy and Safety of Azacitidine Alone or in Combination With Lenalidomide in High-risk Myeloid Disease (High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia) With a Karyotype Including Del(5q NO
Leukemia A Phase II Multi-center, Open Label, Randomized Study to Assess Safety and Efficacy of Two Different Schedules of Oral LDE225 in Adult Patients With Relapsed/Refractory or Untreated Elderly Patients With Acute Leukemia NO
Leukemia A randomized phase II multicenter study with a safety run-in to assess the tolerability and efficacy of the addition of oral lenalidomide to standard induction therapy in AML and RAEB ≥ 66 years and very poor risk AML ≥ 18 years. NO
Leukemia A safety and efficacy study of adding low dose pegylated IFN-alpha 2b to standard dose dasatinib in patients with newly diagnosed chronic phase chronic myeloid leukemia DK
Leukemia A Safety and Efficacy Study of Adding Low Dose Pegylated IFN-alpha 2B to Standard Dose Dasatinib in Patients With Newly Diagnosed Chronic Phase Myeloid Leukemia NO
Lung cancer A multicenter, open-label, randomized phase II study to evaluate the efficacy of AUY922 vs pemetrexed or docetaxel in NSCLC patients with EGFR mutations who have progressed on prior EGFR TKI treatment NO
Lung cancer A Multicenter, Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations Who Have Progressed on Prior EGFR TKI Treatment NO
Lung cancer A phase I/IIa study of UV1 vaccination in patients with non-small cell lung cancer NO
Lung cancer A phase II, multicenter, single-arm study of oral LDK378 in crizotinib naïve adult patients with ALK-activated non-small cell lung cancer NO
Lung cancer IDO Peptide Vaccination for Stage III-IV Non Small-cell Lung Cancer Patients DK
Lung cancer Open randomized phase-II trial of SBRT + chemotherapy vs chemotherapy in NSCLC patients with a maximum of 5 tumor lesions SE
Lung cancer Phase I and II studies of intravenous sodium SElenite as a cytotoxic agent in advanced CARcinoma of the lung SE
Lung cancer Phase I Study of Single Agent MK-3475 in Patients with Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, and Non-Small Cell Lung Carcinoma NO
Lung cancer Phase I Study of Single Agent MK-3475 in Patients With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, and Non-Small Cell Lung Carcinoma NO
Lung cancer Phase II randomized study on Locally Advanced Non small cell lung cancer. Escalated dose on individual basis, treatment with radiochemotherapy SE
Lymphoma Chemo-immunotherapy with early central nervous system (CNS) prophylaxis DK
Lymphoma Dose densified chemoimmunotherapy with early CNS prophylaxis in patients less than 65 years with high risk Diffuse Large B-Cell Lymphoma (NLG-LBC05) FI
Lymphoma Open-Label, Multi-Center, Phase 2 Study of Anti-CCR4 Monoclonal AntibodyKW-0761(mogamulizumab) in Subjects with Previously Treated Peripheral T-Cell Lymphoma (PTCL) DK
Lymphoma Open-label, uncontrolled phase II trial of intravenous PI3K inhibitor BAY-80-6946 in patients with relapsed, indolent or aggressive Non-Hodgkin´s lymphomas FI
Lymphoma Randomised phase II trial on primary chemotherapy with high-dose methtrexate and high-dose cytarabine with or without thiotepa, and with or without rituximab, followed by brain irradiation vs. high-dose chemotherapy supported by autologous stem cell trans DK
Lymphoma Rituximab plus lenalidomide or rituximab monotherapy for untreated patients with follicular lymphoma in need of therapy. A randomized, open-label, multicentre phase II trial SE
Lymphoma, Sarcoma Cross tumoral phase II clinical trial exploring crizotinib (PF-02341066) in patients with advanced tumors induced by causal alterations of ALK and/or MET NO
Melanoma A phase 1 study to evaluate safety, feasibility and immunologic response of adoptive T cell transfer with or without dendritic cell vaccination in patients with metastatic melanoma SE
Melanoma A single arm, open-label, phase II, multicentre study, to assess the safety of vismodegib(GDC-0449) in patients with locally advanced or metastatic basal cell carcinoma (BCC) SE
Melanoma Safety and efficacy of intratumoural electrotransfer of Plasmid AMEP in patients suffering from advanced or metastatic melanoma: an open phase 1 trial DK
Melanoma T-cell therapy for patients with malignant melanoma DK
Melanoma The Melanoma Goup Trial: TOL + vemurafenib followed by interferon + vemurafenib maintenance (BRAF-positive patients) or TOL followed by interferon maintenance (BRAF-negative patients) FI
Melanoma Transfected Dendritic Cell Based Therapy for Patients With Breast Cancer or Malignant Melanoma DK
Multiple diagnosis A phase I, open‐label, multi‐centre, multi‐dose, dose escalation study of LTX‐315 in patients with transdermally accessible tumours NO
Multiple diagnosis A Phase II, Open-label, Study in Subjects with BRAF V600E Mutated Rare Cancers with Several Histologies to Investigate the Clinical Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib NO
Multiple diagnosis Intra-hepatic and systemic chemotherapy with or without antibody for patients with non-resectable liver metastasis from solid tumours DK
Myeloma Daratumumab (anti-CD38) in refractory multiple myeloma, first in humans DK
Myeloma Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma DK
Oesophagus A phase II study with Oxaliplatin + 5-Fu + Cetuximab and radiotherapy for the treatment of non-resectable, locally advanced but not metastatic cancer of oesophagus or the cardia SE
Ovarian cancer A phase II non comparative study with paclitaxel and carboplatin in combination with vorinostat in patients with advanced recurrent epithelia ovarian carcinoma DK
Ovarian cancer DC-006 Recurrent ovarian epithelial cancer NO
Pancreatic cancer A Phase I/II Trial and TG01 Gemcitabine as Adjuvant Therapy for Treating Patients with Resected Adenocarcinoma of the Pancreas NO
Pancreatic cancer Safety, pharmacokinetics and efficacy of AXP107-11 in patients with standard gemcitabine (Gemzar®) treatment in patients with locally advanced or metastatic, unresectable, adenocarcinoma of the pancreas, stage III-IV. SE
Pancreatic cancer Treatment of pancreatic adenocarcinoma by combining contrast agent and gemcitabine under sonication. NO
Prostate cancer A phase I/IIa study of UV1 vaccination in patients with hormone-sensitive metastatic prostate cancer NO
Prostate cancer A Study Looking at Novel Scheduling of Cabazitaxel for Patients With Metastatic Prostate Cancer (ConCab) SE
Prostate cancer DC-005 Prostate NO
Prostate cancer Dendritic cell vaccination in combination with Docetaxel for patients with prostate cancer – a randomized phase II study DK
Sarcoma A Scandinavian Sarcoma Group treatment protocol for adult patients with non-metastatic high-risk soft tissue sarcoma of the extremities and trunk wall SE
Sarcoma Pazopanib in Advanced GISTs Refractory to Imatinib and Sunitinib - A Non-comparative Phase II Multicenter Study by the Scandinavian Sarcoma Group NO
Skin cancer Combined treatment with Autologous Dendritic cells and T cells in patients with advanced Melanoma SE
Solide tumores A Phase I Study of the Safety, Pharmacokinetics and Pharmacodynamics of Escalating Doses of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients with Advanced or Metastatic Solid Tumor Malignancies DK
Solide tumores A phase I, multi-center, open-label, drug-drug interaction study to assess the effect of the CYP1A2 inhibitor, fluvoxamine, on dovitinib (TKI258) pharmacokinetics in patients with advanced solid tumors DK
Solide tumores A phase I, open-label study to evaluate the PK and safety of panobinostat in patients with advanced solid tumors and varying degrees of renal function SE
Solide tumores A phase I/II , open-label study of nivolumab monotherapy or nivolumab combined with ipilimumab in subjects with advanced or metastatic solid tumors FI
Solide tumores A Study of RO5479599 Alone or in Combination With Cetuximab or Erlotinib in Patients With Metastatic and/or Locally Advanced Malignant HER3-Positive Solid Tumors DK
Solide tumores An open non-randomized study to investigate the local tumour control rate in patients with centrally located lung lesions who receive treatment with Stereotactic body radiotherapy SE
Solide tumores An open-level, multicentre, dose-escalation, phase I study with an expansion phase, to evaluate safety, pharmacokinetics and therapeutic activity of RO6895882, an immunocytokine, consisting of a variant of interleukin-2 (IL-2v) targeting carcinoembryonic FI
Solide tumores Phase I dose-escalating study to evaluate the safety and tolerability of LiPlaCis (Liposomal Cisplatin formulation) in patients with advanced or refractory tumours DK
Urothelial A phase II open label, single arm study evaluating treatment with pazopanib post sunitinib treatment in patients with mRCC. SE
Urothelial An exploratory Phase I Study with Sorafenib in Addition to Vinflunine in Progressive Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelial Tract SE